EliA RNA Pol III
Autoantibodies, Anti-Ribonucleic Acid Polymerase (Rnap) Iii Antibody. 510(k) K202541, from Phadia AB (Uppsala, SE). Product code NYO, class 2.
As of Nov 20, 2026, K202541 is an FDA 510(k) held by Phadia AB, substantially equivalent on Sep 13, 2021 after 376 days, with no recalls tied to it in FDA's recall database.
- Review time: 376 days
- Recalls: 0
- Cited as a predicate by: 1 device
EliA RNA Pol III is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNA polymerase III (RNA Pol III) in human serum as an aid in the diagnosis of systemic sclerosis (diffuse form) in conjunction with other laboratory and clinical findings. EliA RNA Pol III uses the EliA IgG method.
- Quanta Lite Rna Pol Iii ElisaK070066 · Inova Diagnostics, Inc. · Apr 11, 2007
- EliA CTD 13 ScreenK253367 · Phadia AB · Jun 25, 2026
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Sep 2, 2020
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5100
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files